About Arvelle Therapeutics
Arvelle Therapeutics is a company based in Zug (Switzerland) founded in 2019 was acquired by Angelini Pharma in January 2021.. Arvelle Therapeutics has raised $222.7 million across 2 funding rounds from investors including Angelini Pharma, Andera Partners and Life Sciences Partners. Arvelle Therapeutics operates in a competitive market with competitors including Marinus Pharma, ORPHELIA Pharma, EpilepsyGTx, Corlieve Therapeutics and Epygenix, among others.
- Headquarter Zug, Switzerland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$222.7 M (USD)
in 2 rounds
-
Latest Funding Round
$42.7 M (USD), Series A
May 26, 2020
-
Investors
Angelini Pharma
& 8 more
-
Employee Count
Employee Count
-
Acquired by
Angelini Pharma
(Jan 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Arvelle Therapeutics
Arvelle Therapeutics has successfully raised a total of $222.7M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $42.7 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $42.7M
-
First Round
First Round
(18 Feb 2019)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Series A - Arvelle Therapeutics | Valuation | NovaQuest Capital Management , BRV Capital Management |
|
| Feb, 2019 | Amount | Series A - Arvelle Therapeutics | Valuation | Life Sciences Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arvelle Therapeutics
Arvelle Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Angelini Pharma, Andera Partners and Life Sciences Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm focused on life science and healthcare companies
|
Founded Year | Domain | Location | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arvelle Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arvelle Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arvelle Therapeutics Comparisons
Competitors of Arvelle Therapeutics
Arvelle Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Marinus Pharma, ORPHELIA Pharma, EpilepsyGTx, Corlieve Therapeutics and Epygenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat seizure disorders
|
|
| domain | founded_year | HQ Location |
Therapies for pediatric neurology, oncology, and hematology are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for focal refractory epilepsy are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurological disorders are developed using AAV gene delivery.
|
|
| domain | founded_year | HQ Location |
Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arvelle Therapeutics
Frequently Asked Questions about Arvelle Therapeutics
When was Arvelle Therapeutics founded?
Arvelle Therapeutics was founded in 2019.
Where is Arvelle Therapeutics located?
Arvelle Therapeutics is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
Is Arvelle Therapeutics a funded company?
Arvelle Therapeutics is a funded company, having raised a total of $222.7M across 2 funding rounds to date. The company's 1st funding round was a Series A of $180M, raised on Feb 18, 2019.
What does Arvelle Therapeutics do?
Arvelle Therapeutics was founded in 2019 in Zug, Switzerland. Small molecule therapies for central nervous system disorders are developed by the firm. The lead candidate, Cenobamate, is targeted at partial-onset seizures in adult patients via GABA-A receptor modulation and sodium current inhibition. Exclusive rights for European development and commercialization were acquired from SK Biopharmaceuticals. An NDA for Cenobamate was filed in February 2019.
Who are the top competitors of Arvelle Therapeutics?
Arvelle Therapeutics's top competitors include Marinus Pharma, ORPHELIA Pharma and Corlieve Therapeutics.
Who are Arvelle Therapeutics's investors?
Arvelle Therapeutics has 9 investors. Key investors include Angelini Pharma, Andera Partners, Life Sciences Partners, KB Investment, and Sio Gene Therapies.